A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia.

Trial Profile

A Phase 2 Study of Imatinib Mesylate (Gleevec) as Maintenance Therapy After Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed C-kit Positive Acute Myeloid Leukemia.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Dec 2015 Primary endpoint (Progression-free survival for patients 60 years of age and older) has not been met as results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 03 Feb 2014 According to ClinicalTrials.gov record planned end date changed from 1 Nov 2013 to 1 Apr 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top